Mammary Cell News 9.46 November 23, 2017 | |
| |
TOP STORYUsing in vivo lineage tracing and triple negative breast cancer (TNBC) patient derived xenografts researchers demonstrated that the repopulating capacity in normal mammary epithelial cells and tumorigenic capacity in TNBC is independent of expression of epithelial to mesenchymal transition-associated genes. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Blimp1 expression marked a rare subpopulation of unipotent luminal stem cells that initially appear in the embryonic mammary gland at around E17.5 coincident with the segregation of the luminal and basal compartments. Fate mapping at multiple time points in combination with whole-mount confocal imaging revealed these long-lived unipotent luminal stem cells survive consecutive involutions and retain their identity throughout adult life. [Nat Commun] Full Article Scientists showed that mammary stem cell (MaSC) and mammary tumor-initiating cell (MaTIC) epithelial–mesenchymal transition programs induce primary cilia formation and Hedgehog signaling, which has previously been implicated in both MaSC and MaTIC function. [Proc Natl Acad Sci USA] Abstract Investigators employed a co-culture model using trabecular bone tissues obtained from total hip replacement surgery specimens to study estrogen receptor-positive and estrogen receptor-negative breast cancer cells within the human bone microenvironment. [Breast Cancer Res] Full Article Researchers applied cell survival assays, immunofluorescence staining, DNA fiber and western blot analyses to look at the correlation between cell survival and genome integrity in control, EEPD1, radiation repair protein 52 (RAD52) and EEPD1/RAD52 co-depletion breast cancer susceptibility protein-1 (BRCA1)-deficient breast cancer cells. [Breast Cancer Res] Full Article Scientists investigated the effect of combining whey protein concentrate with rapamycin on MDA-MB-231 human breast cancer cells. These cells were found to be insensitive to rapamycin and exhibited higher glutathione and reactive oxygen species levels than non-tumorigenic MCF-10A cells. [Sci Rep] Full Article The anti-neoplastic effects of the electrophilic fatty acid nitroalkene derivative, 10-nitro-octadec-9-enoic acid (nitro-oleic acid, NO2-OA), were investigated in multiple preclinical models of triple negative breast cancer (TNBC). NO2-OA reduced TNBC cell growth and viability in vitro, attenuated tumor necrosis factor α-induced TNBC cell migration and invasion and inhibited the tumor growth of MDA-MB-231 TNBC cell xenografts in the mammary fat pads of female nude mice. [J Biol Chem] Abstract Investigators assessed the antitumor activity of the phytosterol α-spinasterol isolated from Ganoderma resinaceum mushroom on human breast cancer cell lines (MCF-7, MDA-MB-231), as well as, on human ovarian cancer cell line (SKOV-3). They showed that α-spinasterol exhibited a higher antitumor activity on MCF-7 cells relative to SKOV-3 cells, while its lowest antitumor activity was against MDA-MB-231 cells. [J Cell Biochem] Abstract Dysregulation of POPDC1 Promotes Breast Cancer Cell Migration and Proliferation The authors assessed the potential of popeye domain-containing protein 1 (POPDC1) as a novel target for inhibiting breast cancer cell migration and proliferation. POPDC1 was significantly suppressed with reduced cell membrane localization in breast cancer cells. [Biosci Rep] Full Article PTK6 Regulates Growth and Survival of Endocrine Therapy-Resistant ER+ Breast Cancer Cells Researchers investigated the functions of PTK6 in ER+ Luminal breast cancer cells, including those that are relatively resistant to estrogen deprivation or targeted endocrine therapies used in the treatment of ER+ cancers. [npj Breast Cancer] Full Article | |
| |
REVIEWSTargeting Protein Quality Control Pathways in Breast Cancer Validated targets for anti-cancer treatments include molecular chaperones, components of the unfolded protein response, the ubiquitin-proteasome system, and autophagy. The authors focus on links between breast cancer and these processes, as well as the development of drug resistance, relapse, and treatment. [BMC Biol] Full Article Extranuclear Signaling by Sex Steroid Receptors and Clinical Implications in Breast Cancer Researchers summarize the current understanding and updates on estrogen receptor (ER) and progesterone receptor (PR) extranuclear signaling. Further investigation of ER/PR extranuclear signaling may lead to development of novel targeted therapeutics for breast cancer management. [Mol Cell Endocrinol] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSPuma Biotechnology, Inc. and Specialised Therapeutics Asia have entered into an exclusive agreement under which Specialised Therapeutics will commercialize NERLYNX® throughout South East Asia, beginning with Australia, Singapore, Malaysia, Brunei and New Zealand. [Puma Biotechnology, Inc. (Business Wire, Inc.)] Press Release NCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer Care The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program and Pfizer Global Medical Grants announced they have awarded funding to nine projects that use clinical care pathways to implement quality improvement initiatives along the continuum of care for underserved patients with breast cancer. [The National Comprehensive Cancer Network®] Press Release Samsung Bioepis Receives Regulatory Approval for Europe’s First Trastuzumab Biosimilar, ONTRUZANT® Samsung Bioepis Co., Ltd. announced the European Commission’s marketing authorization of ONTRUZANT®, a biosimilar referencing Herceptin®, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. [Samsung Bioepis Co., Ltd.] Press Release | |
| |
POLICY NEWSDirector of HHS Scientific Fraud Office Is out after Stormy 2-Year Tenure The controversial director of the office that polices research fraud in U.S.-funded biomedical labs is temporarily moving to another agency. Kathy Partin has been removed after nearly two years as director of the U.S. Office of Research Integrity in Rockville, Maryland, according to Retraction Watch. [ScienceInsider] Editorial European Medicines Agency Will Move to Amsterdam The European Medicines Agency, charged with evaluating human and animal medicinal products for the European Union, will relocate to Amsterdam after it was selected in a draw of lots between it and Milan. [ScienceInsider] Editorial Hungary Rewards Highly Cited Scientists with Bonus Grants Some top researchers prosper in Hungary as country tries to improve its international standing in science. [Nature News] Editorial Sudden Shift at a Public Health Journal Leaves Scientists Feeling Censored For much of its 22-year existence, few outside the corner of science devoted to toxic chemicals paid much attention to the International Journal of Occupational and Environmental Health. But now, a feud has erupted over the small academic publication, as its editorial board — the scientists who advise the journal’s direction and handle article submissions — has accused the journal’s new owner of suppressing a paper and promoting “corporate interests over independent science in the public interest.” [Pro Publica Inc.] Editorial
| |
EVENTSNEW Guy’s and St Thomas’ NHS Foundation Trust: Cancer Genetics Course 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Technician – Breast Cancer (King’s College London) Cancer Bioinformatician – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Research Scientist/Fellow – Breast Cancer (Columbia University) Postdoctoral Training Fellow – Breast Cancer Organoids (Institute of Cancer Research) Executive Director – Breast Cancer Research (Indiana University School of Medicine) Cancer Bioinformatician – Breast Cancer Research (Institute of Cancer Research) PhD Studentships – Cancer Research (University of Cambridge) Postdoctoral Positions – Breast Cancer (Northwestern University- Feinberg School of Medicine) Physician Scientist – Translational Research in Breast Cancers (University of New Mexico) Postdoctoral Fellowship – Breast Cancer Research (Geisel School of Medicine at Dartmouth) Assistant Professor – Cancer Biology (Perelman School of Medicine) Assistant Professor – Cancer Research (University of Minnesota) Postdoctoral Position – Transcriptomics and Cancer Epigenetics (Universität Basel) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|